Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InforSense GenSense Achieves GeneChip-compatible™ Status with the Affymetrix GeneChip® Microarray Platform

Published: Tuesday, August 07, 2007
Last Updated: Tuesday, August 07, 2007
Bookmark and Share
Affymetrix has become a member of InforSense’s Open Workflow Partner Network joining over 40 other partners in the program.

InforSense Ltd. has announced that it has joined the Affymetrix GeneChip-compatible Applications Program, and that its InforSense GenSense solution, has achieved GeneChip-compatible™ status with the Affymetrix GeneChip® microarray platform.

In addition, Affymetrix has become a member of InforSense’s Open Workflow Partner Network (OWPN) joining over 40 other partners in the program.

The integration will enable scientists to analyze and interpret both the Affymetrix Genome-Wide Human SNP 5.0 and SNP 6.0 arrays. Workflows provided with the solution also include access to Affymetrix Power Tools for Loss of Heterozygosity (LOH) and Copy Number Variation (CNV) as well as the Affymetrix calling algorithms, including BRLMM , BRLMM-p and Birdseed.

“We are please to welcome GenSense from Inforsense into the GeneChip-compatible Applications Program,” said Steve Lincoln, Vice-President of Informatics at Affymetrix. “GenSense is deeply integrated with the Affymetrix microarray platform at both the microarray data and annotations levels, enabling researchers to focus more of their efforts on the results and their scientific interpretation."

“Our relationship with Affymetrix enhances our joint customers’ ability to build ad-hoc analysis and data workflows for streamlining Genome Wide Association Studies,” said Jonathan Sheldon, CSO, InforSense. “We are very pleased to have Affymetrix as part of our Open Workflow Partner Network to continue expanding the capabilities available through the InforSense platform.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InforSense Partners with U.K.’s Leading Institutions to Combat Alzheimer’s Disease
Translational research solution to help accelerate early diagnosis and personalized medicine treatments.
Wednesday, December 03, 2008
InforSense® Announces Conference Series
The InforSense Users Conference will provide opportunity to learn how InforSense KDE is being used to facilitate business-critical decision-making across a variety of industries.
Tuesday, November 14, 2006
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!